📊 PCSA Key Takeaways
Is Processa Pharmaceuticals, Inc. (PCSA) a Good Investment?
Processa Pharmaceuticals is a pre-revenue pharmaceutical company with $11.4M in annual operating cash burn against only $5.5M in cash reserves, implying a runway of approximately six months at current burn rates. Despite a clean balance sheet with minimal debt, the absence of revenue generation combined with an unsustainable burn rate presents fundamental financial distress incompatible with any positive investment thesis.
Why Buy Processa Pharmaceuticals, Inc. Stock? PCSA Key Strengths
- Minimal debt burden with Debt/Equity ratio near zero and only $27.5K long-term debt
- Strong short-term liquidity with Current Ratio of 2.54x and Quick Ratio of 2.47x
- Modest 89.3% YoY improvement in diluted EPS trajectory suggesting operational optimization
PCSA Stock Risks: Processa Pharmaceuticals, Inc. Investment Risks
- Zero revenue with no visible commercialization pathway or production capability
- Critical cash runway of approximately six months at current $11.4M annual burn rate
- High pharmaceutical R&D execution risk with uncertain clinical pipeline and regulatory approval uncertainty
- Dependence on future capital raises to survive, creating severe dilution risk to equity
Key Metrics to Watch
- Quarterly cash balance and updated runway projections relative to burn rate
- Clinical trial milestones, FDA interactions, and regulatory pathway clarity
- Debt or equity financing announcements and capital structure changes
Processa Pharmaceuticals, Inc. (PCSA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.54x current ratio provides a solid financial cushion.
PCSA Profit Margin, ROE & Profitability Analysis
PCSA vs Healthcare Sector: How Processa Pharmaceuticals, Inc. Compares
How Processa Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Processa Pharmaceuticals, Inc. Stock Overvalued? PCSA Valuation Analysis 2026
Based on fundamental analysis, Processa Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Processa Pharmaceuticals, Inc. Balance Sheet: PCSA Debt, Cash & Liquidity
PCSA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Processa Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-96.78 indicates the company is currently unprofitable.
PCSA Revenue Growth, EPS Growth & YoY Performance
PCSA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | N/A | -$2.1M | $-0.08 |
| Q2 2023 | N/A | -$2.6M | $-0.10 |
| Q1 2023 | N/A | -$3.2M | $-0.18 |
| Q3 2022 | N/A | -$2.1M | $-0.19 |
| Q2 2022 | N/A | -$2.1M | $-0.20 |
| Q1 2022 | N/A | -$2.1M | $-0.14 |
| Q3 2021 | N/A | -$733.4K | N/A |
| Q2 2021 | N/A | -$733.4K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Processa Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
PCSA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Processa Pharmaceuticals, Inc. (CIK: 0001533743)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PCSA
What is the AI rating for PCSA?
Processa Pharmaceuticals, Inc. (PCSA) has an AI rating of STRONG SELL with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PCSA's key strengths?
Claude: Minimal debt burden with Debt/Equity ratio near zero and only $27.5K long-term debt. Strong short-term liquidity with Current Ratio of 2.54x and Quick Ratio of 2.47x.
What are the risks of investing in PCSA?
Claude: Zero revenue with no visible commercialization pathway or production capability. Critical cash runway of approximately six months at current $11.4M annual burn rate.
What is PCSA's revenue and growth?
Processa Pharmaceuticals, Inc. reported revenue of $0.0.
Does PCSA pay dividends?
Processa Pharmaceuticals, Inc. pays dividends, with $0.0M distributed to shareholders in the trailing twelve months.
Where can I find PCSA SEC filings?
Official SEC filings for Processa Pharmaceuticals, Inc. (CIK: 0001533743) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PCSA's EPS?
Processa Pharmaceuticals, Inc. has a diluted EPS of $-10.36.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PCSA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Processa Pharmaceuticals, Inc. has a STRONG SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PCSA stock overvalued or undervalued?
Valuation metrics for PCSA: ROE of -243.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PCSA stock in 2026?
Our dual AI analysis gives Processa Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PCSA's free cash flow?
Processa Pharmaceuticals, Inc.'s operating cash flow is $-11.4M, with capital expenditures of $3.2K.
How does PCSA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -243.2% (avg: 15%), current ratio 2.54 (avg: 2).